Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

from thought-leaders and have offset some of the financial burden of running proof-of-concept studies. The Company has already taken steps to improve our prospects in future partnering discussions from a corporate structure standpoint, and we will continue to improve MANF's prospects by focusing on further differentiating MANF from its competition, especially in Parkinson's disease. To further this objective, we have added certain key advisors to assist management in preparing a winning strategy to obtain the most value from our MANF program. With these new additions, we have gained access to significant intellectual capital, as well as invaluable insight into the realm of preparing both our asset and our corporation for successful partnerships.

MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.

Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and ... addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... report deals with therapeutic drug monitoring, a ... care by monitoring drug levels in the ...
(Date:5/28/2015)... May 27, 2015 Research and ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Neuroprotection - ... This report describes the role of ... injuries of the nervous system as well as ... many of the underlying mechanisms of damage to ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3
... Biosciences,Incorporated (Nasdaq: KOSN ) today announced that ... as Chief Executive Officer, effectively immediately.,Ms. Kim joined ... and Chief,Business Officer, and was appointed President in ... of the Board, commented: "We,believe that Helen possesses ...
... and,the president of one of the area,s major ... Committee as winners of the region,s third,bioscience award ... Region Bioscience Awards are:, -- Best New ... CEO, CSA,Medical, Inc. Askew,s very young Baltimore-based company ...
... Study Successfully Hit Primary End Point of ... Toward Superiority over the Market Leader, ... (NASDAQ: ANPI , TSX: ANP), a ... today that the clinical data from its ...
Cached Biology Technology:Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 2Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 3Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 4Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... brain, cells talk to one another through the routine ... a deep sleep, the higher regions of the brain ... grid of neural dialogue - apparently lose their ability ... today (Sept. 30) in the journal Science, a team ...
... tied to lifespan extension in yeast have been identified by ... reducing calorie intake, or caloric restriction, is known to extend ... research linked a gene called Sir2 with lifespan extension due ... also live longer when put on a tough diet, showing ...
... A combination of the drugs ribavirin and interferon is ... alone, but it also increases the risk of side ... evidence. , "Adding ribavirin to any type of interferon ... with hepatitis C," conclude Jesper Brok, M.D., and colleagues ...
Cached Biology News:Deep sleep short-circuits brain's grid of connectivity 2Deep sleep short-circuits brain's grid of connectivity 3Hepatitis C responds best to combo of ribavirin and interferon, study concludes 2Hepatitis C responds best to combo of ribavirin and interferon, study concludes 3
... The DIGIVIEW line of digital x-ray ... radiation imaging device complete with 12 to ... area consists of a photodiode array sensor ... All models are available in low x-ray ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... XCAT 50 X-Ray System from KUBTEC is a ... two and three dimensional representation of the specimen ... reconstruction of specimen X-ray images, the micro focus ... level of detail in standard 2D images. The ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
Biology Products: